Claudin 1 over-expression in breast carcinoma correlates with better prognosis and lower incidence of axillary lymph node metastasis [17, 18]; while its decreased expression is associated with higher incidence of recurrence and lymph node metastasis and short disease free interval [18]. Here, CLDN1 is linked to metastatic malignant neoplasm in the lymph nodes.